Ivabradine significantly reduces cardiovascular death or hospitalization for worsening heart failure irrespective of baseline systolic blood pressure.1
Ivabradine also reduces cardiovascular mortality (P interaction=0.91), hospitalization for worsening heart failure (P interaction=0.79), all-cause mortality (P interaction=0.90), and heart failure mortality (P interaction=0.18) irrespective of baseline systolic blood pressure.1
1. Komajda M et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. Eur J Heart Fail. 2014;16(7):810-816.